Oncotarget

Research Papers:

Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases

Chong Zhao, Xin Chen, Changshan Yang, Dan Zang, Xiaoying Lan, Siyan Liao, Peiquan Zhang, Jinjie Wu, Xiaofen Li, Ningning Liu, Yuning Liao, Hongbiao Huang, Xianping Shi, Lili Jiang, Xiuhua Liu, Q. Ping Dou, Xuejun Wang, Jinbao Liu _

PDF |  HTML  |  Author Information  |  Order a Reprint

Oncotarget. 2017; 8:13942-13956. https://doi.org/10.18632/oncotarget.14572

Metrics: PDF 381 views  |   HTML 170 views  |   ?  


Abstract

Chong Zhao1,2,*, Xin Chen1,*, Changshan Yang1,*, Dan Zang1, Xiaoying Lan1, Siyan Liao1, Peiquan Zhang1, Jinjie Wu1, Xiaofen Li1, Ningning Liu1,3, Yuning Liao1, Hongbiao Huang1, Xianping Shi1, Lili Jiang1, Xiuhua Liu4, Q. Ping Dou5, Xuejun Wang1,6, Jinbao Liu1

1State Key Laboratory of Respiratory Disease, Protein Modification and Degradation Laboratory, Department of Pathophysiology, Guangzhou Medical University, Guangdong 510182, China

2Department of Gastroenterology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China

3Guangzhou Research Institute of Cardiovascular Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510260, China

4Institute of Environmental and Analytical Sciences, College of Chemistry and Chemical Engineering, Henan University, Kaifeng, Henan 475004, China

5The Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, Michigan 48201-2013, USA

6Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, South Dakota 57069, USA

*These authors have contributed equally to this work

Correspondence to:

Jinbao Liu, email: jliu@gzhmu.edu.cn

Xuejun Wang, email: xuejun.wang@usd.edu

Keywords: zinc pyrithione, proteasome, deubiquitinases, DNA damage, tumor

Received: November 08, 2016     Accepted: December 27, 2016     Published: January 10, 2017

ABSTRACT

The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.

Author Information

Chong Zhao

Xin Chen

Changshan Yang

Dan Zang

Xiaoying Lan

Siyan Liao

Peiquan Zhang

Jinjie Wu

Xiaofen Li

Ningning Liu

Yuning Liao

Hongbiao Huang

Xianping Shi

Lili Jiang

Xiuhua Liu

Q. Ping Dou

Xuejun Wang

Jinbao Liu
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14572